Senores Pharmaceuticals Limited
CLOSEDIPO Date: 20 Dec - 24 Dec 2024
Listing Date: 30 Dec 2024
Price Range
₹372 to ₹391 per share
Issue Size
582.11 Cr
Min Investment
₹14,136
Lot Size
38 Shares
Schedule of Senores Pharmaceuticals Limited
Issue open date
20 Dec 2024
Issue close date
24 Dec 2024
UPI mandate deadline
24 Dec 2024 (5 PM)
Allotment finalization
26 Dec 2024
Share credit
27 Dec 2024
Listing date
30 Dec 2024
Mandate end date
8 Jan 2025
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 582.11 Cr |
| Fresh Issue | 0 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 26 Dec 2024 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|
Performance Senores Pharmaceuticals Limited
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹372 to ₹391 per share | .... | .... | .... |
About Senores Pharmaceuticals Limited
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.The company's manufacturing unit is situated in Ahmedabad, Gujrat.
| Founded in | 2017 |
| Managing director | |
| Parent organization |
Financial Overview
Strengths
- The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
- A unique product portfolio tailored for regulated markets developed in a brief period.
- Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
- Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
- Robust R&D capabilities driving our differentiated portfolio of products.
- Experieced Management Team
Risks
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 97.84 |
| Non-Institutional Investors (NIIs) | 100.35 |
| Retail Individual Investors (RIIs) | 93.16 |
| Employee | N/A |
| Total | 97.86 |